Who Could Buy Bristol-Myers Squibb?
Billionaire activist investor Carl Icahn has reportedly set his sights on Bristol-Myers Squibb ( NYSE:BMY ) , a $90 billion-market-cap biopharma that's carving out an important leadership position in immuno-oncology. If past is prologue, Icahn's about to start advocating for big changes at Bristol-Myers Squibb, and those could include an outright sale. Finding a buyer, however, might not be easy...
Login to comment.